private digital health companies obesity management glp-1 Receptor Agonist Market Size Innovation at the sweet Size:Value 28-Pack Skin_Type: Dry

private digital health companies obesity management glp-1 Receptor Agonist Market Size Innovation at the sweet Size:Value 28-Pack Skin_Type: Dry

Innovation at the sweet spot: GLP-1, allulose and the rise of “post-sweeteners”

Developed by Novo Nordisk, WEGOVY (semaglutide) is a GLP-1 receptor agonist designed to support sustainable weight loss when paired with a balanced diet and regular physical activity

Skin_Type: Dry

Size:Value 28-Pack

While a 2024 FDA Drug Safety Communication did not find an increased association between depressive symptoms and suicidal thoughts in patients taking GLP-1 RAs, it nonetheless recommended that patients be closely monitored for such symptoms until more data is available